title: Pediatric non-Hodgkin's lymphoma abdominal presentations: a comparative study between two treatment regimens at the National Cancer Institute Cairo.
abstract: Abdominal presentations of pediatric NHL are rarely amenable to complete surgical resection. Chemotherapy is the hallmark of treatment for pediatric NHL. Treatment of various types of this disease including intra-abdominal NHL in children with various protocols have not exceeded 54 per cent two-year disease-free survival. We have attempted to study and compare the effects of two treatment regimen upon two groups of previously untreated children up to the age of 16 years who presented to the Pediatric Oncology Unit at the NCI. The first group included 18 children who presented between 1983 and 1985 and were treated by a modified St Jude regimen: while the second group of patients was comprised of 19 children who presented between 1985 and 1987 and were treated by a multi-national protocol: the MCP 842. The two groups will be compared with respect to various patient characteristics, response to therapy and their two-year disease-free survival as well as overall survival.
authors.affiliation: Department of Pediatric Oncology, National Cancer Institute, Cairo University, Egypt.
authors.forename: S S
authors.initials: SS
authors.lastname: Abdel Hadi
authors.forename: O M
authors.initials: OM
authors.lastname: el Taneer
authors.forename: M H
authors.initials: MH
authors.lastname: Hussein
authors.forename: A
authors.initials: A
authors.lastname: el Haddad
authors.forename: S
authors.initials: S
authors.lastname: el Badawi
authors.forename: N
authors.initials: N
authors.lastname: Mokhtar
authors.forename: M R
authors.initials: MR
authors.lastname: Hamza
authors.forename: N G
authors.initials: NG
authors.lastname: el Mawla
mesh_terms: D000008:Abdominal Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000592:standards / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D004534:Egypt / Q000453:epidemiology; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage / Q000627:therapeutic use; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D011379:Prognosis; D015996:Survival Rate; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D003561:Cytarabine; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D007069:Ifosfamide; D008727:Methotrexate